124 related articles for article (PubMed ID: 27410930)
1. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Rees DC
N Engl J Med; 2016 Jul; 375(2):185-6. PubMed ID: 27410930
[No Abstract] [Full Text] [Related]
2. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Badawy SM
N Engl J Med; 2016 Jul; 375(2):185. PubMed ID: 27410931
[No Abstract] [Full Text] [Related]
3. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
[TBL] [Abstract][Full Text] [Related]
4. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N; Rees DC
Expert Opin Investig Drugs; 2017 Jul; 26(7):865-872. PubMed ID: 28562105
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease.
Reams SG; Messana L; Brown PB; Nanry K; Gunnell AE
Contemp Clin Trials; 2018 Jan; 64():88-94. PubMed ID: 29104118
[TBL] [Abstract][Full Text] [Related]
7. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.
Tripathi A; Jerrell JM; Stallworth JR
Ann Hematol; 2011 Feb; 90(2):145-50. PubMed ID: 20714723
[TBL] [Abstract][Full Text] [Related]
9. Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
Torres L; Conran N
Expert Opin Pharmacother; 2019 Feb; 20(2):173-186. PubMed ID: 30499731
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Moser BA; LaBell ES; Chigutsa E; Jakubowski JA; Small DS
Clin Pharmacokinet; 2018 Feb; 57(2):243-254. PubMed ID: 28578536
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
12. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
[TBL] [Abstract][Full Text] [Related]
13. [The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
Abaci A
Turk Kardiyol Dern Ars; 2015 Oct; 43 Suppl 2():1-6. PubMed ID: 27326444
[TBL] [Abstract][Full Text] [Related]
14. [Prasugrel in clinical practice: Frequently asked questions].
Simşek MA; Değertekin MM
Turk Kardiyol Dern Ars; 2015 Oct; 43 Suppl 2():25-9. PubMed ID: 27326448
[TBL] [Abstract][Full Text] [Related]
15. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
[TBL] [Abstract][Full Text] [Related]
16. Current Antiplatelet Agents in Acute Coronary Syndrome.
Sachdeva A
J Assoc Physicians India; 2015 Jan; 63(1):75-6. PubMed ID: 26591137
[No Abstract] [Full Text] [Related]
17. The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia.
DeBaun MR; Strunk RC
Lancet; 2016 Jun; 387(10037):2545-53. PubMed ID: 27353685
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Gunarathne A; Hussain S; Gershlick AH
Expert Rev Cardiovasc Ther; 2016 Nov; 14(11):1215-1226. PubMed ID: 27701930
[TBL] [Abstract][Full Text] [Related]
19. Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
Chin CT; Neely B; Magnus Ohman E; Armstrong PW; Corbalán R; White HD; Prabhakaran D; Winters KJ; Fox KA; Roe MT;
Stroke; 2016 Apr; 47(4):1135-9. PubMed ID: 26883498
[TBL] [Abstract][Full Text] [Related]
20. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
Jakubowski JA; Erlinge D; Alexopoulos D; Small DS; Winters KJ; Gurbel PA; Angiolillo DJ
Am J Cardiovasc Drugs; 2017 Apr; 17(2):109-121. PubMed ID: 27854064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
